Dual hypoxia-responsive supramolecular complex for cancer target therapy

Jian Shuang Guo, Juan Juan Li, Ze Han Wang, Yang Liu, Yu Xin Yue, Hua Bin Li, Xiu He Zhao, Yuan Jun Sun, Ya Hui Ding, Fei Ding, Dong Sheng Guo*, Liang Wang*, Yue Chen

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

14 Citations (Scopus)

Abstract

The prognosis with pancreatic cancer is among the poorest of any human cancer. One of the important factors is the tumor hypoxia. Targeting tumor hypoxia is considered a desirable therapeutic option. However, it has not been translated into clinical success in the treatment of pancreatic cancer. With enhanced cytotoxicities against hypoxic pancreatic cancer cells, BE-43547A2 (BE) may serve as a promising template for hypoxia target strategy. Here, based on rational modification, a BE prodrug (NMP-BE) is encapsulated into sulfonated azocalix[5]arene (SAC5A) to generate a supramolecular dual hypoxia-responsive complex NMP-BE@SAC5A. Benefited from the selective load release within cancer cells, NMP-BE@SAC5A markedly suppresses tumor growth at low dose in pancreatic cancer cells xenograft murine model without developing systemic toxicity. This research presents a strategy for the modification of covalent compounds to achieve efficient delivery within tumors, a horizon for the realization of safe and reinforced hypoxia target therapy using a simple approach.

Original languageEnglish
Article number5634
JournalNature Communications
Volume14
Issue number1
DOIs
Publication statusPublished - Dec 2023
Externally publishedYes

Fingerprint

Dive into the research topics of 'Dual hypoxia-responsive supramolecular complex for cancer target therapy'. Together they form a unique fingerprint.

Cite this